Cereno Scientific obtains patent protection in major market Japan for Phase II drug candidate CS1
Cereno Scientific today announced that drug candidate CS1 has obtained strengthened intellectual property rights (IPR) in Japan, one of the world’s largest pharmaceutical markets. The patent protection for CS1’s second patent family now covers key markets with previously granted markets, the US and Russia, as well as Japan. This adds to the growing portfolio of issued patents secured for Cereno’s assets to strengthen the commercial positioning.“Japan is one of the world’s largest pharmaceutical markets, only behind the US and marginally China. The patent protection for CS1 now covering two